# Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

> **NCT00715637** · PHASE3 · UNKNOWN · sponsor: **Antisoma Research** · enrollment: 420 (estimated)

## Conditions studied

- Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

## Interventions

- **DRUG:** Daunorubicin and Cytarabine
- **DRUG:** Amonafide and Cytarabine

## Key facts

- **NCT ID:** NCT00715637
- **Lead sponsor:** Antisoma Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-06
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2010-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00715637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00715637, "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00715637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*